Antiretroviral Agents in HIV-1 (2018)

Antiretroviral Agents in HIV-1 Pocket Guide

DHHS HIV GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/370315

Contents of this Issue

Navigation

Page 17 of 29

18 Selecting a Treatment Regimen Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Efavirenz (EFV) Sustiva ® 600 mg PO once daily, at or before bedtime No dosage adjustment necessary Child-Pugh Class A: • No dosage adjustment Child-Pugh Class B/C: • NOT recommended Etravirine (ETR) Intelence ® 200 mg PO bid No dosage adjustment necessary Child-Pugh Class A/B: • No dosage adjustment Child-Pugh Class C: • No dosage rec. Nevirapine (NVP) Viramune ® Viramune ® XR • 200 mg PO bid, or • 400 mg PO once daily (using Viramune XR formulation) Patients on HD: • Limited data; no dosage recommendation Child-Pugh Class A: • No dosage adjustment Child-Pugh Class B/C: • Contraindicated Rilpivirine (RPV) Edurant ® 25 mg PO once daily No dosage adjustment necessary Child-Pugh Class A/B: • No dosage adjustment Child-Pugh Class C: • No dosage rec. Protease Inhibitors (PIs) Atazanavir (ATV) Reyataz ® 400 mg PO once daily OR ATV 300 mg + RTV 100 mg PO once daily No dosage adjustment for patients with renal dysfunction who do not require HD ARV-Naive Patients on HD: • ATV 300 mg + RTV 100 mg once daily ARV-Experienced Patients on HD: • ATV or ATV/r NOT recommended Child-Pugh Class B: • 300 mg once daily Child-Pugh Class C: • NOT recommended RTV boosting is NOT recommended in patients with hepatic impairment (Child-Pugh Class B or C). Atazanavir/ COBI (ATV/c) Evotaz ® 1 tablet PO once daily If Used with TDF: • NOT recommended for use in patients with CrCl <70 mL/min NOT recommended in patients with hepatic impairment Table 6. Dosing of Antiretroviral Agents (cont'd) ARVs Generic Name (Abbreviation) Trade Name Usual Daily Dose a Dosing in Renal Insufficiency b Dosing in Hepatic Impairment

Articles in this issue

Archives of this issue

view archives of Antiretroviral Agents in HIV-1 (2018) - Antiretroviral Agents in HIV-1 Pocket Guide